Leadership - Scientific Advisory Board
Epizyme's Scientific Advisory Board provides expertise from target identification and validation, through enzymology and animal models, to clinical development and oncology. Each member actively engages with Epizyme’s scientists to rapidly translate cutting-edge research into our innovative therapeutic programs.
Epizyme Scientific Co-Founder
Dr. Horvitz received the Nobel Prize in Physiology or Medicine in 2002. He is the David H. Koch Professor of Biology at the Massachusetts Institute of Technology; an Investigator of the Howard Hughes Medical Institute; Neurobiologist (Neurology) and Geneticist (Medicine) at the Massachusetts General Hospital; and a Member of the McGovern Institute for Brain Research and the MIT Center for Cancer Research.
Dr. Horvitz received S.B. degrees in Mathematics and in Economics from the Massachusetts Institute of Technology in 1968. He performed his graduate studies at Harvard University in the laboratories of Drs. James Watson and Walter Gilbert and received his Ph.D. in 1974. Dr. Horvitz was a postdoctoral fellow in the laboratory of Dr. Sydney Brenner at the Medical Research Council Laboratory of Molecular Biology in Cambridge, England.
Dr. Horvitz is a member of the SAB of the Novartis Institutes for Biomedical Science and is chair of the Medical and Scientific Advisory Board of the venture capital company MPM Capital. Dr. Horvitz has co-founded five biotechnology companies and served on the SABs of 11 biotechnology companies.
Epizyme Scientific Co-Founder
Dr. Zhang is a Professor of Biochemistry and Biophysics at the University of North Carolina Chapel Hill. He is also an Investigator of the Howard Hughes Medical Institute.
Yi Zhang earned an undergraduate degree and an M.S. at the College of Biological Sciences, China Agricultural University, in the People’s Republic of China. He received a Ph.D. at the Institute of Molecular Biophysics of Florida State University in Tallahassee.
Dr. Zhang has won the Gertrude B. Elion Cancer Research Award from the American Association of Cancer Research and the Sidney Kimmel Foundation for Cancer Research Scholar Award.
Dr. Chabner serves as a Clinical Director for the Massachusetts General Hospital Cancer Center, is the Chief of Hematology/Oncology in the Department of Medicine, and a Professor of Medicine at Harvard Medical School.
He received his B.A., summa cum laude, from Yale College and an M.D. cum laude, from Harvard Medical School.
Dr. Chabner has received the Public Health Service’s Distinguished Service Medal, the Karnofsky Award of the American Society for Clinical Oncology and the Bruce F. Cain Award for Drug Development of the American Association for Cancer Research.
Dr. Daley is the Samuel E. Lux IV Professor of Hematology/Oncology and the Director of the Stem Cell Transplantation Program at Children's Hospital Boston and the Dana Farber Cancer Institute. He is also Professor in the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School and an investigator of the Howard Hughes Medical Institute.
Dr. Daley earned his bachelor's degree magna cum laude from Harvard University, his Ph.D. from MIT, and his M.D. summa cum laude from Harvard Medical School.
Dr. Daley has been elected a member of the Institute of Medicine of the US National Academy of Sciences, American Society for Clinical Investigation, American Association of Physicians, American Pediatric Societies, American Academy of Arts and Sciences, and American Association for the Advancement of Science, and has received the NIH Director¹s Pioneer Award, the Judson Daland Prize from the American Philosophical Society, the E. Mead Johnson Award from the American Pediatric Society, and the E. Donnall Thomas Prize from the American Society for Hematology.
Dr. Evans, a professor in the Gene Expression Laboratory, is the March of Dimes Chair in Developmental and Molecular Biology. Dr. Evans is an authority on hormones, both their normal activities and their roles in disease.
He received his B.A. in Bacteriology from the University of California, Los Angeles and his Ph.D. in Microbiology and Immunology from the University of California, Los Angeles.
A major achievement in Dr. Evans' lab was the discovery of a large family of molecules, named receptors, which respond to various steroid hormones, Vitamin A and thyroid hormones. The receptors Dr. Evans discovered are primary targets in the treatment of breast cancer, prostate cancer and leukemia, as well as osteoporosis and asthma.
Dr. Henikoff is currently an Investigator of the Howard Hughes Medical Institute, a Member of the Basic Sciences Division of the Fred Hutchinson Cancer Research Center, and Affiliate Professor of Genome Sciences at the University of Washington.
He received a Ph.D. degree in biochemistry and molecular biology at Harvard University in the laboratory of Matthew Meselson, and did postdoctoral research with Charles Laird at the University of Washington.
He is a Member of the US National Academy of Sciences, and serves as co-Editor-in-chief of the journal Epigenetics and Chromatin. His laboratory studies histone variants, DNA methylation, epigenetic inheritance and centromere evolution, and develops tools for epigenomics and functional genomics.
Dr. Huff retired in 2004 from his position of Vice President of Medicinal Chemistry at Merck Research Laboratories following 30 years of service.
He received his B.S. in Chemistry from the University of Texas, Austin, and a Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology.
At Merck he led efforts to develop therapeutic agents for HIV, resulting in the discovery of indianvir (Crixivan®), and efavirenz (Stocrin®, Sustiva®). Dr. Huff has authored or co-authored 98 publications and patents.
Dr. Jacks is the David H. Koch Professor of Biology and Director of the Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology. As a postdoctoral fellow with Robert Weinberg at the Whitehead Institute at MIT, Dr. Jacks initiated his studies on tumor-suppressor gene function.
He received his A.B. degree in biology from Harvard College and his Ph.D. degree in biochemistry and biophysics from UCSF.
Tyler Jacks is interested in the genetics of cancer development. His laboratory has constructed a series of mutant mouse strains that have served as animal models of tumor development and as a means to study the functions of cancer-associated genes.
Dr. Walsh is the Hamilton Kuhn Professor of Biological Chemistry and Molecular Pharmacology (BCMP) at Harvard Medical School.
After completing undergraduate studies at Harvard University, Dr. Walsh earned his Ph.D. from the Rockefeller University.
Dr. Walsh and his group have authored 700 research papers and 3 books. Dr. Walsh has also served on many boards and in many capacities to leading innovators in biotechnology.